Pan-Ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by Zaire and Sudan viruses
Nature Communications·
- DOI
- 10.1038/s41467-026-76114-1
- PMID
- 42702625
- PMCID
- —
- OpenAlex
- W7201999174
- Study type
- Journal article
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Findings support continued development of a pan-ebolavirus vaccine built on the I53-50 platform, which has established clinical safety, and may be relevant for populations at risk of EBOV and SUDV outbreaks.
Structured evidence summary
Research question
The study investigates whether self-assembling I53-50 nanoparticles displaying prefusion Zaire ebolavirus or Sudan ebolavirus glycoprotein antigens can elicit protective immune responses against lethal Ebolavirus challenge in rodent models.
Study design
Preclinical vaccine study involving design, structural characterization, and in vivo evaluation of nanoparticle immunogens in mice and guinea pig models, including homologous and heterologous challenge conditions.
Population and setting
Laboratory rodents consisting of mice (including a mouse-adapted EBOV model) and guinea pigs (including a guinea pig-adapted SUDV model).
Main findings
EBOV-GP and SUDV-GP nanoparticle immunogens produced strong homologous protection in rodents. Cocktail and mosaic formulations gave weaker than matched protection in the mouse-adapted EBOV model, whereas in the guinea pig-adapted SUDV model they conferred robust protection and detectable antibody responses to both GPs.
Public-health relevance
Findings support continued development of a pan-ebolavirus vaccine built on the I53-50 platform, which has established clinical safety, and may be relevant for populations at risk of EBOV and SUDV outbreaks.
Important limitations
The summary is limited to the supplied single-article abstract and metadata; the original paper is required for decision-grade interpretation. The abstract does not explicitly state limitations, but evident scope constraints include evaluation only in rodent models rather than primates or humans and variable performance of mosaic versus cocktail formats across the two challenge models.
GIDS interpretation
The article is indexed under Ebola hemorrhagic fever, One Health, outbreak investigation, and vaccination topics, indicating relevance for discoverability by users monitoring filovirus vaccine research, though no connection to a live surveillance signal is implied.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 12 auditable classifier relationships to diseases, places, topics, and study design.